Protalix BioTherapeutics (PLX) Assets (2010 - 2026)
Protalix BioTherapeutics (PLX) posted quarterly Assets of $102.3 million for Q1 2026, up 38.49% year-over-year from $73.9 million in Q1 2025, and up 24.28% quarter-over-quarter from $82.3 million in Q4 2025.
Protalix BioTherapeutics (PLX) Assets (2010 - 2026) Analysis & Trends
Protalix BioTherapeutics' Assets history runs 17 years deep, the most recent figure standing at $102.3 million for Q1 2026.
- In Q1 2026, Assets rose 38.49% year-over-year to $102.3 million; the TTM figure through Mar 2026 stood at $102.3 million (up 38.49% YoY), while the FY2025 annual figure was $82.3 million, up 12.16% from the prior year.
- Assets for Q1 2026 stood at $102.3 million, up from $82.3 million in the prior quarter.
- The five-year high for Assets was $102.3 million in Q1 2026, with the low at $55.8 million in Q4 2022.
- The 5-year median for Assets is $78.5 million (2025), against an average of $76.7 million.
- The sharpest annual moves came in 2022 and 2023: Assets plunged 43.96% in 2022, then surged 54.42% in 2023.
- Protalix BioTherapeutics' Assets stood at $55.8 million in 2022, then surged by 51.35% to $84.4 million in 2023, then declined by 13.05% to $73.4 million in 2024, then grew by 12.16% to $82.3 million in 2025, then climbed by 24.28% to $102.3 million in 2026.
- Business Quant data shows PLX's Assets at $102.3 million in Q1 2026, $82.3 million in Q4 2025, and $82.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.56 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.10 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.60 Bn |
| 10 | Protalix BioTherapeutics | 190.37 Mn | 149.71 Mn | 12.13 Mn | 110.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 110.34 Mn |
| Mar 31, 2026 | 102.34 Mn |
| Dec 31, 2025 | 82.35 Mn |
| Sep 30, 2025 | 82.26 Mn |
| Jun 30, 2025 | 78.49 Mn |
| Mar 31, 2025 | 73.89 Mn |
| Dec 31, 2024 | 73.42 Mn |
| Sep 30, 2024 | 61.56 Mn |
| Jun 30, 2024 | 91.54 Mn |
| Mar 31, 2024 | 89.83 Mn |
| Dec 31, 2023 | 84.43 Mn |
| Sep 30, 2023 | 87.57 Mn |
| Jun 30, 2023 | 88.42 Mn |
| Mar 31, 2023 | 66.56 Mn |
| Dec 31, 2022 | 55.79 Mn |
| Sep 30, 2022 | 56.71 Mn |
| Jun 30, 2022 | 60.64 Mn |
| Mar 31, 2022 | 68.39 Mn |
| Dec 31, 2021 | 73.67 Mn |
| Sep 30, 2021 | 83.48 Mn |